3.1 Severe Asthma & COPD Exacerbations in the ICU

Acute exacerbations of obstructive airway disease—encompassing acute severe asthma (status asthmaticus) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD)—represent frequent, high-stakes medical emergencies in the intensive care unit. While both conditions present with expiratory airflow limitation, tachypnea, and respiratory distress, their underlying cellular pathophysiology, airway mechanics, dynamic response to positive pressure ventilation, and evidence-based indications for noninvasive versus invasive support differ significantly.

---

Pathophysiology of Airflow Limitation

Expiratory airflow limitation in obstructive airway diseases arises from marked increases in airway resistance ($R_{\text{aw}}$) and altered respiratory system elastance ($E_{\text{rs}}$).

Acute Severe Asthma

In status asthmaticus, the primary pathology is intense, acute smooth muscle contraction coupled with airway wall mucosal edema, eosinophilic and neutrophilic inflammation, and extensive intraluminal inspissation of tenacious mucus plugs throughout the bronchial tree.

Because lung parenchymal architecture and alveolar elastic recoil are largely preserved, airflow limitation in asthma is primarily dynamic and resistance-driven. The high resistance markedly prolongs the expiratory time constant of the respiratory system ($\tau = R_{\text{aw}} \times C_{\text{rs}}$), requiring substantially longer duration for passive exhalation.

Chronic Obstructive Pulmonary Disease (COPD)

In AECOPD, airflow limitation results from a combination of chronic small airway inflammation (bronchiolitis with peribronchiolar fibrosis) and irreversible destruction of the alveolar capillary bed and parenchymal matrix (pulmonary emphysema).

The progressive loss of radial alveolar tethering reduces the outward mechanical traction on small conducting airways, leading to dynamic expiratory airway collapse. In COPD, the equal pressure point—the anatomic locus along the airway where intraluminal pressure matches peribronchial tissue pressure—shifts upstream toward small, non-cartilaginous bronchioles during active exhalation, resulting in premature airway closure and profound gas trapping.

---

Dynamic Hyperinflation, Auto-PEEP, and Hemodynamics

The Mechanism of Gas Trapping

When respiratory rate and airway resistance are elevated, the expiratory time ($T_E$) allotted by the patient's breathing cycle or ventilator settings is shorter than the time required for passive deflation back to the relaxed functional residual capacity (FRC). Subsequent inspiration begins before full exhalation is completed, causing progressive air trapping—a state termed dynamic hyperinflation.

This trapped alveolar gas exerts positive pressure throughout the lung parenchyma at end-expiration, creating intrinsic positive end-expiratory pressure (auto-PEEP).

Dynamic Airflow Obstruction (High Raw) + Short Expiratory Time (TE)
                           │
                           ▼
        Incomplete Passive Alveolar Emptying
                           │
                           ▼
      Progressive Air Trapping (Dynamic Hyperinflation)
                           │
                           ▼
          Auto-PEEP (Intrinsic Alveolar Pressure)
              ┌────────────┴────────────┐
              ▼                         ▼
   Inspiratory Threshold Load   Hemodynamic Collapse
 (Increased Work of Breathing) (Decreased Venous Return)

Measuring Auto-PEEP

In an intubated, passively ventilated patient (without spontaneous respiratory efforts), auto-PEEP is quantified on the mechanical ventilator by executing an end-expiratory hold maneuver for 2 to 3 seconds:

1. At end-expiration, the expiratory valve closes, preventing gas escape.
2. Alveolar pressure equilibrates with the pressure transducer in the ventilator circuit.
3. The total measured pressure represents total PEEP ($P_{\text{tot}}$).
4. Auto-PEEP is calculated as:

$\text{auto-PEEP} = P_{\text{tot}} - \text{PEEP}_{\text{extrinsic}}$

Hemodynamic Compromise and the "Tamponade of the Lung"

Dynamic hyperinflation produces profound circulatory derangements:

• Reduced Venous Return: Elevated intrathoracic pressure compresses the superior and inferior vena cava and right atrium, collapsing the extrathoracic-to-intrathoracic venous pressure gradient and drastically reducing right ventricular (RV) preload.
• Increased RV Afterload: Alveolar overdistension stretches and compresses intra-alveolar capillaries, increasing pulmonary vascular resistance (PVR).
• Ventricular Interdependence: RV dilation within the constrained pericardial space shifts the interventricular septum leftward, compressing the left ventricle (LV), impairing LV diastolic filling, and precipitating sudden cardiogenic/obstructive shock.
• Arrest Phenomenon: In extreme breath-stacking, cardiac output drops to near-zero, culminating in pulseless electrical activity (PEA) arrest.

---

Noninvasive Ventilation: COPD vs. Asthma

Noninvasive Ventilation in COPD

Noninvasive positive-pressure ventilation (NIV/BiPAP) is a cornerstone of therapy in acute hypercapnic respiratory failure from COPD ($\text{pH} < 7.35$ and $\text{PaCO}_2 > 45\text{ mmHg}$).

By delivering an inspiratory positive airway pressure (IPAP) that supplements tidal breathing and an expiratory positive airway pressure (EPAP) that counterbalances auto-PEEP, NIV drastically reduces diaphragmatic work, reverses acute hypercapnic encephalopathy, shortens hospital length of stay, and prevents endotracheal intubation and its attendant complications (ventilator-associated pneumonia, tracheal injury, difficult weaning).

Noninvasive Ventilation in Asthma

In severe asthma, evidence supporting NIV is markedly weaker. Severe asthma is characterized by dynamic diffuse bronchospasm and thick secretions rather than the dynamic airway collapse seen in emphysema. High positive airway pressures can exacerbate air trapping and induce barotrauma (pneumothorax, pneumomediastinum).

NIV should only be trialed in highly selected, fully conscious, cooperative asthmatic patients with mild-to-moderate respiratory acidosis who do not exhibit signs of imminent exhaustion. If clear improvement in tachypnea, work of breathing, and gas exchange is not evident within 60 to 90 minutes, prompt endotracheal intubation is mandatory.

Contraindications to NIV

• Respiratory arrest or gasping respirations
• Inability to clear copious respiratory secretions or frank hemoptysis
• Severe encephalopathy or coma (Glasgow Coma Scale score $< 8$)
• Uncooperative, combative, or agitated delirium
• Facial trauma, severe burns, or craniofacial anatomic abnormalities precluding mask fit
• Acute upper gastrointestinal hemorrhage, bowel obstruction, or intractable vomiting (high aspiration risk)
• Severe hemodynamic instability requiring escalating vasoactive infusions

---

Endotracheal Intubation & Airway Management

Indications for Invasive Mechanical Ventilation

• Progression to respiratory arrest or severe bradypnea
• Profound exhaustion manifested by "silent chest" (disappearance of wheezing and breath sounds due to minimal airflow)
• Altered mental status: lethargy, stupor, or agonal agitation
• Worsening respiratory acidosis ($\text{pH} < 7.15–7.20$) despite intensive pharmacotherapy and noninvasive trials
• Refractory hypoxemia ($\text{PaO}_2 < 60\text{ mmHg}$ on maximal supplemental oxygen)
• Hemodynamic collapse, refractory shock, or life-threatening arrhythmias

Critical Airway Risks During Intubation

Intubating an individual with severe bronchospasm is one of the most perilous airway procedures in critical care. Two lethal complications frequently occur during or immediately following induction:

1. Profound Post-Induction Hypotension: Rapid loss of endogenous sympathetic tone from sedative agents, compounded by immediate conversion from negative-pressure spontaneous ventilation to high positive-pressure ventilation, severely curtails venous return. Intravascular volume expansion with 500 to 1,000 mL crystalloid should be administered preemptively.
2. Catastrophic Breath-Stacking: Manual bag-valve-mask hyperventilation at rates of 20 to 30 breaths/min traps immense volumes of gas in seconds, creating high intrathoracic pressure and immediate electromechanical dissociation.

Rapid Sequence Intubation Strategy

• Induction Agent: Ketamine (1.5–2.0 mg/kg IV) is the agent of choice. It triggers endogenous catecholamine release, relaxes bronchial smooth muscle via NMDA receptor antagonism and muscarinic pathway inhibition, and maintains systemic vascular tone.
• Paralytic Agent: Rocuronium (1.2 mg/kg IV) or succinylcholine (1.5 mg/kg IV). Rocuronium is preferred when prolonged paralysis is anticipated to allow ventilator synchronization. Histamine-releasing muscle relaxants (such as atracurium) must be avoided.
• Tube Caliber: Select a large endotracheal tube (ETT $\ge 8.0\text{ mm}$ inner diameter for adults). Airway resistance through an ETT is inversely proportional to the fourth power of the radius (Poiseuille's law); larger tubes dramatically reduce resistance and facilitate subsequent bronchoscopy and suctioning.

---

Mechanical Ventilation Strategy in Severe Bronchospasm

The overarching principle of mechanical ventilation in status asthmaticus and severe COPD is lung protection through dynamic decompression. Clinicians must avoid the temptation to normalize arterial blood gases, adhering instead to the paradigm of permissive hypercapnia.

Ventilator Goals in Severe Bronchospasm:
┌──────────────────────────────┬──────────────────────────────┐
│ Ventilator Parameter         │ Target Goal                  │
├──────────────────────────────┼──────────────────────────────┤
│ Mode                         │ Volume Control (Assist/Ctrl) │
│ Tidal Volume (VT)            │ 6–8 mL/kg PBW (often 5–7)    │
│ Respiratory Rate (RR)        │ 10–14 breaths/min            │
│ Peak Inspiratory Flow        │ 70–90 L/min (Square wave)    │
│ Inspiratory:Expiratory (I:E) │ 1:3 to 1:5                   │
│ Plateau Pressure (Pplat)     │ ≤30 cmH2O                    │
│ Permissive Hypercapnia       │ pH ≥7.15–7.20 (PaCO2 60–90)  │
└──────────────────────────────┴──────────────────────────────┘

Setting the Ventilator

• Tidal Volume ($V_T$): 6 to 8 mL/kg of predicted body weight (PBW). In extreme asthma, reducing $V_T$ to 5 to 6 mL/kg PBW may be necessary to control plateau pressures.
• Respiratory Rate ($RR$): 10 to 14 breaths/min. A low rate is the single most effective intervention to prolong expiratory time ($T_E$) and allow complete exhalation.
• Inspiratory Flow Rate: Deliver gas at a high peak inspiratory flow rate of 70 to 90 L/min (up to 100 L/min) using a square or descending decelerating waveform. High inspiratory flow shortens the inspiratory time ($T_I$), thereby expanding available $T_E$ to achieve an $I:E$ ratio of 1:3, 1:4, or 1:5.
• Extrinsic PEEP ($P_{\text{ext}}$):
  • In Asthma: Set PEEP to zero (ZEEP) or minimal ($0–5\text{ cmH}_2\text{O}$). In asthma, airflow obstruction is diffuse and resistance-mediated (bronchospasm, mucus plugging, wall edema) rather than caused by dynamic expiratory collapse, so extrinsic PEEP is more likely to add to end-expiratory lung volume and barotrauma risk.
  • In COPD: In patients who are triggering the ventilator, set extrinsic PEEP to approximately 70% to 80% of measured auto-PEEP (in a fully passive patient it offers little benefit). In COPD, airway closure is dynamic. Applying extrinsic PEEP splints open dynamically collapsed downstream airways, acting like a "waterfall" to reduce the inspiratory threshold work of breathing without elevating upstream alveolar pressure.

Plateau Pressure vs. Peak Inspiratory Pressure

Clinicians must differentiate between peak inspiratory pressure ($P_{\text{peak}}$) and plateau pressure ($P_{\text{plat}}$):

$P_{\text{peak}} = \left( \text{Flow} \times R_{\text{aw}} \right) + P_{\text{plat}}$

• $P_{\text{peak}}$ is frequently elevated to 50 to 70 cmH2O in severe bronchospasm due to extreme resistance across conducting airways and the endotracheal tube. Elevated $P_{\text{peak}}$ alone does not rupture alveoli and is not an independent marker of barotrauma.
• $P_{\text{plat}}$ (measured with a 0.5-second end-inspiratory pause) reflects static alveolar distending pressure. To protect the lung from alveolar rupture and barotrauma, $P_{\text{plat}}$ must be maintained $\le 30\text{ cmH}_2\text{O}$.

---

Medical Management of Severe Bronchospasm in the ICU

First-Line Inhaled Therapies:
├── Continuous nebulized albuterol (10–20 mg/hr) or MDI with in-line spacer (4–8 puffs q15–30min)
└── Inhaled ipratropium bromide (0.5 mg nebulized q4–6h)

Systemic Pharmacotherapy:
├── Systemic corticosteroids: asthma - methylprednisolone 40–60 mg IV q6–12h; COPD - prednisone 40 mg daily x 5 days (or IV equivalent)
├── Intravenous magnesium sulfate: 2 g IV over 20 minutes (blocks smooth-muscle calcium influx)
└── Ketamine infusion: 0.5–2.0 mg/kg/hr IV for bronchodilatory sedation

Refractory Rescue Options:
├── Inhalational volatile anesthetics (sevoflurane, isoflurane via ICU vaporizers)
├── Neuromuscular blockade: Cisatracurium infusion (to eliminate ventilator dyssynchrony)
└── Extracorporeal Membrane Oxygenation: Veno-venous (VV) ECMO for refractory hypercapnic arrest

Pharmacologic Adjuncts

• Inhaled Beta-2 Agonists: Albuterol delivered continuously (10 to 20 mg/hr) or via frequent metered-dose inhalers (MDIs) with an in-line spacer chamber (4 to 8 puffs every 15 to 30 minutes).
• Inhaled Anticholinergics: Ipratropium bromide (0.5 mg nebulized every 4 to 6 hours) acts synergistically with beta-agonists by blocking muscarinic bronchoconstriction.
• Systemic Corticosteroids: In severe asthma, methylprednisolone 40 to 60 mg IV every 6 to 12 hours (oral prednisone is equally effective when it can be absorbed; higher doses add toxicity without proven benefit) accelerates resolution of airway inflammation and restores beta-2 receptor responsiveness. In COPD exacerbations, prednisone 40 mg daily for 5 days was noninferior to 14 days in the REDUCE trial; use the IV equivalent in intubated patients.
• Antibiotics in AECOPD: Give antibiotics when sputum purulence accompanies increased dyspnea or sputum volume, and for every patient who needs NIV or invasive ventilation; they reduce treatment failure and, in ventilated patients, mortality. Antibiotics are not routinely indicated in asthma unless pneumonia or another bacterial infection is present.
• Intravenous Magnesium Sulfate: 2 grams IV infused over 20 minutes (can be repeated once). Magnesium inhibits voltage-gated calcium channels in bronchial smooth muscle, producing direct relaxation.
• Continuous Ketamine: An infusion of 0.5 to 2.0 mg/kg/hr provides combined analgosedation and smooth muscle bronchodilation.
• Inhalational Anesthetics: Volatile agents (isoflurane, sevoflurane) delivered via dedicated ICU volatile gas scavenging delivery systems (such as the Anaesthetic Conserving Device) directly relax bronchial smooth muscle in life-threatening refractory status asthmaticus.
• Neuromuscular Blockade: A continuous infusion of cisatracurium eliminates patient-ventilator dyssynchrony, tachypnea, and chest wall rigidity that exacerbate breath-stacking. Continuous paralytic use should be limited to the minimum effective duration ($< 24–48\text{ hours}$) and monitored with peripheral nerve stimulation (train-of-four) to mitigate the high risk of acute quadriplegic myopathy of intensive care, especially when co-administered with high-dose corticosteroids.

---

Acute Decompression for Breath-Stacking & Sudden Hypotension

If an intubated patient with severe obstructive airway disease develops sudden hemodynamic collapse, profound bradycardia, or pulseless electrical activity (PEA):

Sudden Hypotension / PEA Arrest in Mechanically Ventilated Obstructive Patient
                                  │
                                  ▼
   STEP 1: IMMEDIATELY DISCONNECT PATIENT FROM VENTILATOR CIRCUIT
                                  │
                                  ▼
   STEP 2: PERFORM MANUAL BILATERAL CHEST WALL COMPRESSION
           (Evacuates trapped alveolar volume; wait 15–30 sec)
                                  │
              ┌───────────────────┴───────────────────┐
              ▼                                       ▼
   Hemodynamics Restore Within 30s        Persistent Collapse / Absent Breath Sounds
              │                                       │
              ▼                                       ▼
Diagnosis: Dynamic Hyperinflation        Evaluate for Tension Pneumothorax
(Auto-PEEP Overdistension)               Perform Immediate Needle/Finger Thoracostomy
Reconnect ventilator with:               Followed by Tube Thoracostomy
• Lower RR (10–12 bpm)
• Lower VT (5–6 mL/kg PBW)
• Higher peak flow (80–90 L/min)
• Zero/low extrinsic PEEP